Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Group 1 (patients planning surgery):
- You are under 75 years old and have been diagnosed with prostate cancer confirmed by a tissue biopsy (specifically a type called invasive adenocarcinoma)
- Your cancer is considered intermediate to high risk, with at least a 5% chance of the cancer having spread to nearby lymph nodes, based on a specific medical calculation tool (the Briganti nomogram)
- You are scheduled to have your prostate surgically removed, along with an extended removal of nearby lymph nodes
Group 2 (patients whose cancer has returned after treatment):
- You have been diagnosed with prostate cancer confirmed by a tissue biopsy
- Your PSA blood test level has risen to 0.2 ng/ml or above on two separate tests after having had a main prostate treatment (such as surgery or radiotherapy)
- You are generally well enough to carry out light activity and care for yourself (confirm with trial site)
- You are over 18 years old
Who may not be able to join:
Group 1:
- Your scans (MRI) have already shown that cancer has spread to lymph nodes in the pelvis
- Your bone scan shows the cancer has spread to the bones (if your PSA level is above 20 ng/ml)
- Your general health and ability to carry out daily activities is significantly limited (confirm with trial site)
- You have previously had radiotherapy to the pelvic area or prostate removal surgery
- You have had another type of cancer in the last 5 years, other than a successfully treated common skin cancer (basal cell carcinoma)
- There are personal, family, social, or location-related reasons that might make it difficult for you to follow the trial's schedule and requirements (confirm with trial site)
Group 2:
- Your testosterone level in your blood is below 50 ng/ml
- You have cancer spread (metastases) that is causing symptoms
- Your MRI scan shows the cancer has come back in the area where the prostate was
- Your PSA level has been rising while you are already on hormone-related treatments for prostate cancer (confirm with trial site for specific treatments)
- You have previously had chemotherapy for prostate cancer
- You have taken certain medications in the past month that are known to affect PSA levels, such as fluconazole, finasteride, or steroids (confirm with trial site)
- You have a condition that prevents you from understanding the trial information or giving your agreement to take part
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Karolien Goffin, MD, PhD, UZ Leuven
Phone: 003216343714
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
68Ga-PSMA PET/MR imaging accuracy before radical prostatectomy + pelvic lymph node dissection [RP + PLND]. Work unit 1. 68Ga-PSMA PET/MR imaging accuracy in patients with biochemical recurrence after primary treatment. Work unit 2.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.